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Abstract
In pregnant women, cardiovascular complications are among the causes of maternal death, one of which is 
peripartum cardiomyopathy (PPCM). The similarity in the mechanism of PPCM and pre-eclampsia makes 
preeclampsia a risk factor for PPCM. Preeclampsia, together with PPCM, also contributes to the increasing 
maternal mortality when most of the causes of maternal death are preventable.  This case study aimed to provide 
descriptions as the basis in education, raising public awareness, early detection, and early treatment, especially 
for patients at risk. Eight PPCM cases with preeclampsia were identified during the period of 2017–2018 in 
Dr. Hasan Sadikin General Hospital Bandung, Indonesia (RSHS). Cases of PPCM with preeclampsia are rarely 
reported in RSHS. Out of 8 patients, 7 experienced severe preeclampsia and 1 had impending eclampsia. Diagnosis 
in PPCM patients requires a complete history taking, physical examination, and other diagnostic tests such as 
echocardiography. In this study, all patients (100%) complained of dyspnea on exertion as a chief complaint and, 
based on the New York Heart Association in 1994, 87.5% were included in functional class III–IV. The average 
ejection fraction was shown to be 34.6%, indicating a value below normal limit.
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Studi Kasus Dekompensasi Jantung pada Pasien Preeklampsia dan 
Kardiomiopati Peripartum
Abstrak
Pada wanita hamil, komplikasi kardiovaskular berperan dalam kematian ibu, salah satunya adalah kardiomiopati 
peripartum (PPCM). Persamaan patogenesis antara PPCM dan pre-eklampsia menjadikan preeklampsia sebagai 
faktor risiko untuk PPCM. Preeklampsia bersama dengan PPCM berperan dalam peningkatan angka kematian ibu 
(AKI) ketika sebagian besar penyebab AKI dapat dicegah. Studi kasus ini bertujuan diharapkan untuk memberikan 
deskripsi sebagai dasar dalam pendidikan, meningkatkan kesadaran masyarakat, deteksi dini, dan perawatan dini, 
terutama untuk pasien yang berisiko. Pada tahun 2017–2018, terdapat 8 kasus pasien PPCM dengan preeklampsia 
yang dirawat di RSUP Dr. Hasan Sadikin Bandung (RSHS). Kasus PPCM dengan preeklampsia jarang dilaporkan di 
RSHS. Dari 8 pasien, 7 pasien mengalami preeklamsia berat dan 1 pasien dengan impending eclampsia. Diagnosis 
pada pasien PPCM memerlukan anamnesis yang lengkap, pemeriksaan fisik, dan pemeriksaan penunjang seperti 
ekokardiografi. Pada penelitian ini, semua pasien (100%) mengeluhkan sesak nafas sebagai keluhan utama dan 
berdasar atas klasifikasi New York Heart Association tahun 1994, 87,5% termasuk dalam kelas fungsional III–IV. 
Rata-rata fraksi ejeksi menunjukkan 34,6% yang menandakan nilai di bawah batas normal.
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Introduction
Peripartum cardiomyopathy (PPCM) is a rare 
case of heart failure secondary to left ventricular 
systolic dysfunction that occurs at the end of 
pregnancy and several months postpartum.1 
The incidence varies between countries around 
the world. A high incidence of PPCM is observed 
in Haiti (1 per 300 births) and Nigeria (1 per 
100 births) whereas Japan has a much lower 
incidence rate with 1 per 20.000 births.2,3 These 
variabilities are influenced by several risk factors 
such as race, inadequate nutrition intake, and 
hypertension status.2
The similarity in the mechanism of 
peripartum cardiomyopathy and preeclampsia, 
which is one of the hypertensive complications 
in pregnancy, has been observed. An increase 
in placental soluble fms-like tyrosine kinase 1 
(sFlt-1) in preeclampsia patients is also seen in 
PPCM patients. Increased sFlt-1 and decreased 
peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC-α) give rise to 
angiogenic disorders and account for cardiac 
dilation.1,4,5 These resemblances in several 
mechanisms during the course of the two 
diseases, such as genetic predisposition (TTN 
gene) and an increase in antiangiogenic factors, 
make preeclampsia one of the risk factors of 
PPCM.4 
Peripartum cardiomyopathy has a high 
mortality rate despite the rarity of the disease.6 In 
the United States, 26.5% of maternal mortalities 
are caused by cardiovascular diseases, with PPCM 
accounts for 23% of deaths during the postpartum 
period.7 On the other hand, preeclampsia has 
high incidence and mortality rates. According to 
the World Health Organization, the incidence of 
preeclampsia is seven times higher in developing 
countries.8 In Indonesia, preeclampsia and other 
hypertensive complications in pregnancy are 
the second leading cause of maternal mortality.9 
Undiagnosed preeclampsia and PPCM that do not 
receive adequate therapy will lead to maternal 
mortalities that will eventually increase the 
maternal mortality ratio (MMR).
Data from the Indonesian Ministry of Health 
data in 2012 presented that about 52.6% of 
maternal mortality occurs in 6 large provinces, 
one of which is West Java Province. In the same 
year, the Expanding Maternal and Neonatal 
Survival (EMAS) program has succeeded to 
decrease the MMR to 305 per 100.000 live 
births, which is still far below the Sustainable 
Development Goals’ (SDGs) target of reducing 
MMR to 70 per 100.000 live births in 2030.10 
Maternal deaths are caused by complications 
that are actually preventable. Thus, the role of 
the primary, secondary, and tertiary prevention 
is essential, especially for the high-risk pregnant 
women, including those who have a high risk for 
preeclampsia. 
To be able to provide appropriate prevention 
and treatment for PPCM, a good understanding 
of the disease is required. Hence, good studies on 
this condition are very much needed.
Despite the widely available individual 
studies on preeclampsia and peripartum 
cardiomyopathy, studies on PPCM with 
preeclampsia patients are still scarce, especially 
in Indonesia. There is one study available 
that described the characteristics of 20 PPCM 
patients with preeclampsia in 2014–2016 at 
Dr. Soetomo, Surabaya, Indonesia; nevertheless, 
data and studies on PPCM with preeclampsia 
in West Java are still difficult to find.11 This 
study aimed to report the rare cases of PPCM 
and preeclampsia among patients visiting Dr. 
Hasan Sadikin General Hospital Bandung, as 
one of the referral hospitals in West Java. It is 
expected that the results can be used as inputs in 
medical education, raise public awareness, and 
enable early detection and immediate treatment, 
especially for patients at risk.
Case
A series of PPCM cases were collected 
retrospectively from the inpatient medical 
records of Dr. Hasan Sadikin General Hospital 
Bandung during the period of 2017–2018. Eight 
cases of PPCM patients with preeclampsia were 
identified. All patients met the following criteria: 
(1) no history of previous cardiac structure 
disorder; (2) diagnosed with preeclampsia; 
(3) diagnosed with PPCM in peripartum or 
postpartum period and (4) ejection fraction 
<45%. 
In general, two patients had a sign and 
symptoms that were similar to the left heart 
failure, such as dyspnea on exertion, orthopnea, 
paroxysmal nocturnal disease, coughing with 
phlegm, and fine crackles. Meanwhile, six other 
patients had a sign and symptoms similar to the 
left and right heart failure, with an addition of 
increased jugular venous pressure and/or lower 
extremities edema. The presentation of the 
cases is shown in Table 1. Seven patients were 
diagnosed with severe preeclampsia and 50% 
were diagnosed with PPCM in the postpartum 
period (Table 2). All patients complained of 
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Table 1 Patients Characteristics







Dilation EF (%)Enlarge Sound
1 34 Y.O, G3P2A0
Severe 
preeclampsia 160/100 90 + Murmur LA-LV 27
2 28 Y.O, G1P0A0
Severe 
preeclampsia 160/110 120 + Normal LV 35
3 19 Y.O, G1P0A0
Severe 
preeclampsia 160/110 142 - Normal - 41
4 36 Y.O, G1P0A0
Severe 
preeclampsia 160/100 98 +
S3, S4, 
murmur LV 36
5 28 Y.O, G2P1A0
Severe 
preeclampsia 140/90 150 -
S3, S4, 
murmur - 32
6 35 Y.O, G4P1A2
Severe 
preeclampsia 140/90 148 + Normal LA-LV 38
7 20 Y.O, G1P0A0
Severe 
preeclampsia 160/100 114 + Normal LA-LV 43
8 21 Y.O, G1P0A0
Impending 
eclampsia 149/108 110 - Normal - 25
Notes: GPA: gravida, para, abortus; Y.O: years old; BP: blood pressure; HR: heart rate; LA: left atrium; LV: left ventricle;  
             EF: ejection fraction
Table 2 Patient Characteristics
Characteristics n (%)
Age
Mean (Stdev) 26.4 (6.12)
<30 years old 6 (75%)








Severe preeclampsia 7 (87.5%)
Impending eclampsia 1 (12.5%)






Notes: PPCM: peripartum cardiomyopathy; NYHA: New 
York Heart Association
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dyspnea on exertion as their chief complaint. 
Other signs and symptoms are presented in 
Table 3.
Of the eight cases, only four cases underwent 
electrocardiography examinations. All showed 
sinus tachycardia. In one case, there was also a 
poor R wave progression and an old anteroseptal 
myocardial infarction while in two cases, left 
ventricular hypertrophy and a poor R wave 
progression were observed. X-ray was only 
performed in one patient with the result showing 
right pleural effusion and cardiomegaly without 
pulmonary congestion. Echocardiography 
results are presented in Table 4. All patients had 
an ejection fraction of <45% with an average of 
34.6%.
Of these 8 patients, 4 were diagnosed with 
peripartum cardiomyopathy in the antepartum 
period and choice of drugs given are presented 
in table 5 while the medications for patients that 
were diagnosed during the postpartum period 
are presented in Table 6.
Discussion
Peripartum cardiomyopathy (PPCM) is a heart 
failure secondary to left ventricular systolic 
dysfunction that occurs at the end of pregnancy 
and several months post-delivery.1 A previous 
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Table 4 Echocardiography Results
Echocardiography f (%)
Heart Chamber Dilation
Left atrium and ventricle 3 (37.5%)
Left ventricle 2 (25%)
No dilation 3 (37.5%)
Ejection Fraction
Mean (Stdev) 34,6 (6,3)
Global hypokinetic 8 (100%)
Left ventricular systolic dysfunction 7 (87.5%)




Low probability 1 (12.5%)
High probability 1 (12.5%)
Heart Valve Disorders
Trivial MR 1 (12.5%)
Structural TR 1 (12.5%)
Mild MR 3 (37.5%)
Mild TR 1 (12.5%)
Mild PR 1 (12.5%)
Mild AR 1 (12.5%)
Moderate TR 1 (12.5%)
Notes: MR: mitral regurgitation; TR: tricuspid 
regurgitation; PR: pulmonary regurgitation; AR: aortic 
regurgitation
Table 3 Signs and Symptoms of Heart Failure




Cough with phlegm 3 (37.5%)
Tachycardia 7 (87.5%)
Increased JVP 3 (37.5%)
HJR positive 2 (25%)
Cardiomegaly 6 (75%)
S3 heart sound 2 (25%)
S4 heart sound 2 (25%)
Murmur 3 (37.5%)
Bilateral fine crackling sound 6 (75%)
Lower extremities edema 6 (75%)
Notes: DOE: dyspnea on exertion; PND: paroxysmal 
nocturnal dyspnea; JVP: jugular venous pressure; HJR: 
hepatojugular reflux
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study defines PPCM as an idiopathic and new-
onset heart failure that occurs in a patient at the 
end of pregnancy or during the first 5 months 
post-delivery.4 In this study, 4 patients were 
diagnosed with PPCM during the postpartum 
period.
In the United States, cardiovascular diseases 
remain the major cause (26.5%) of maternal 









deaths, with peripartum cardiomyopathy 
accounts for 23% of deaths in postpartum.7 The 
incidence of PPCM varies across regions with 
Haiti (1 per 300 birth) and Nigeria (1 per 100 
birth) show a high incidence. The incidence of 
PPCM in Japan is much lower with 1 per 20.000 
birth.3 These variabilities are influenced by 
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several risk factors such as race, inadequate 
nutrition intake and hypertensive complications, 
such as preeclampsia.2
Risk factors for peripartum cardiomyopathy 
include maternal age ≥30 years old, black race, 
multiple gestation, multiparity, hypertension, 
anemia, autoimmune disease, thyroid 
dysfunction, malnutrition, smoking, diabetes, 
and tocolysis use.1,2,4 In this case study, risk factors 
were identified as follows: 2 patients were ≥30 
years old, 2 patients had multiple gestation, and 
4 patients were multiparity. These are different 
from the previous studies because the sample 
size and the study duration were limited in this 
case study. 
Preeclampsia is one of the risk factors for 
peripartum cardiomyopathy. A study on 535 
PPCM patients revealed that 29.3% of PPCM 
patients were preeclamptic.12 Another study 
in Dr. Hasan Sadikin General Hospital Bandung 
discovered that 26.3% of PPCM patients were 
preeclamptic.13 Preeclampsia is classified 
based on its severity into preeclampsia and 
severe preeclampsia. In this study, 7 patients 
were diagnosed with severe preeclampsia 
and 1 patient was diagnosed with impending 
eclampsia. This is similar to the previous study, 
where 18 cases with severe preeclampsia and 1 
case with eclampsia were identified.11 
Preeclampsia and peripartum cardiomyopathy 
have a similar pathogenesis. Some studies stated 
that genetic, inflammation, and unbalanced 
angiogenesis factors influence the correlation 
between the two diseases.1,2,4,5 In preeclamptic 
patients, placental hypoxia accelerates the 
placental soluble fms-like tyrosine kinase 1 
(sFlt-1) secretion, causing vascular endothelial 
growth factors and placental growth factors 
fail to bind with their receptor, reflecting their 
roles in endothelial dysfunction mechanism.15,16 
Increased sFlt-1 level is also seen in PPCM 
patients.1,4,5 The loss of peroxisome proliferator-
activator receptor gamma coactivator 1-alpha 
(PGC-α) and the increase in sFlt-1 cause the 
heart to be unprotected and also become the 
reason why PPCM occurs late in pregnancy 
and during the postpartum period. Changes in 
the balance of angiogenesis that is caused by 
preeclampsia increase the risk in PPCM patients 
with susceptibility to heart problems.17
In diagnosing peripartum cardiomyopathy 
patients, complete history taking is important 
to exclude other differential diagnoses.1 In 
general, patients would experience signs and 
symptoms of heart failure such as dyspnea on 
exertion, orthopnea, paroxysmal nocturnal 
dyspnea, and lower extremities edema. On 
physical examination, signs associated with left 
and right heart failure such as pulmonary rales, 
increased jugular venous pressure, and edema 
can be observed.4 In this study, all patients 
complained about dyspnea on exertion as their 
chief complaint. 
The postpartum sFlt-1 concentration level 
relates to the functional class of the New York 
Heart Association (NYHA) in patients.2,4 The 
ninth edition of NYHA has classified heart 
failure based on its functional capacity. In this 
case series, 7 patients were classified to NYHA 
functional class III-IV and 1 patient was classified 
to NYHA functional class I-II. By location, heart 
failure can also be classified as left heart failure, 
right heart failure, or both.18 In this study, 6 
patients had signs and symptoms similar to left 
and right heart failure while the remaining 2 had 
left heart failure. This finding is similar to that of 
the previous study.4
Laboratory examination results usually show 
increasing B-type natriuretic peptide, N-terminal 
pro-BNP, and troponin levels. However, in 
patients with preeclampsia without PPCM 
there is also an increase in atrial natriuretic 
peptides, brain natriuretic peptides, and cystatin 
C.19 Imaging such as cardiovascular magnetic 
resonance imaging and computed tomography 
scan can also be performed but endomyocardial 
biopsy is not permitted to be used to diagnose 
PPCM patients.4
In peripartum cardiomyopathy patients, 
electrocardiography (ECG) would reveal sinus 
rhythm and is mostly accompanied by a T wave 
abnormality.4 Only four out of eight in this study 
were examined using ECG. The ECG results 
were similar to that of the previous study with 
the majority of patients experienced sinus 
tachycardia (100%). Some patients also revealed 
poor R wave progression (75%), left ventricular 
hypertrophy (50%), and old anteroseptal 
myocardial infarction. 
On radiography examination, peripartum 
cardiomyopathy patients usually show 
pulmonary edema and enlarged heart silhouette.4 
In this case series, the chest x-ray was only 
performed in one patient, showing cardiomegaly, 
which is similar to the one in the previous study. 
The patient did not have pulmonary congestion 
but pleural effusion is one of the signs of cardiac 
decompensation. 
Preeclamptic patients with heart failure 
manifestation do not always have peripartum 
cardiomyopathy. Changes in blood vessels in 
preeclamptic patients will cause an increase 
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in arterial blood pressure and total vascular 
resistance. Increased vasoconstriction plays a 
role in increasing the afterload of the left ventricle 
and causing a decrease in cardiac output. Thus, 
patients have impaired left ventricular function 
that is characterized by concentric hypertrophy 
and diastolic and systolic dysfunctions.19 
 Echocardiography is the main modality 
in diagnosing peripartum cardiomyopathy. 
This examination can distinguish whether 
preeclampsia patients have PPCM or not. 
Preeclampsia patients without PPCM usually 
have preserved ejection fraction.19 The diagnosis 
of PPCM is made when there is left ventricular 
dysfunction with an ejection fraction of <45% 
during peripartum or early postpartum period 
and without any history of structural heart 
disease.1,4 
All patient’s echocardiographic results 
showed an ejection fraction of <45% with 
the highest and lowest EF of 41% and 25%, 
respectively. The mean value of EF was 34.6%, 
which indicates that patients had left ventricular 
function that is below the normal range.  The 
lowest EF (25%) belonged to the PPCM patient 
with impending eclampsia. However, it is 
unknown whether the severity of preeclampsia 
affects the low value of left ventricular ejection 
fraction or not. A study in Barnes-Jewish Hospital 
to assess left ventricular ejection fraction 
recovery during a follow-up in PPCM patients 
with and without preeclampsia shows that the 
EF in PPCM patients with preeclampsia are more 
likely to recover to the normal range. 20
In this present study, 3 patients showed left 
atrial-ventricular dilatation, 2 patients showed 
left ventricular dilatation only, and 3 patients did 
not have any cardiac chamber dilatation. This is 
similar to the finding in the previous study that 
stated left ventricular dilatation does not always 
occur in these patients.1,4 
Heart failure that occurs in peripartum 
cardiomyopathy patients can develop rapidly. 
Thus, the management used for these patients 
is the same management for heart failure.1,4 In 
Dr. Hasan Sadikin General Hospital Bandung, 
the management for PPCM patients is based 
on the European Society of Cardiology (ESC) 
guideline.13 According to the ESC guideline 
in 2018, the essential therapy for PPCM 
management, which is referred to as BOARD, 
consists of bromocriptine, oral heart failure 
therapies, anticoagulant, vasoRelaxing agent, 
and diuretics.1
Medication in pregnant and nursing mothers 
is quite challenging due to the consideration that 
must be taken regarding the ability of the drugs 
to cross the placental barriers and to be excreted 
with breast milk to avoid any side effects on 
the fetus and breastfed baby. Medicines that 
are toxic to the fetus include angiotensin-
converting enzyme inhibitor, angiotensin II 
receptor blocker, angiotensin receptor neprilysin 
inhibitor, mineralocorticoid receptor blocker, 
and atenolol. These drugs should not be given 
to pregnant women.1,4,13 For patients diagnosed 
in antepartum, the choice of drugs may include 
hydralazine, nitrate, and beta 1 selective 
blockers. Diuretic (loop diuretic and thiazide) 
administration can be considered when there is 
an indication of pulmonary edema.1,4 
Four of the respondents who were diagnosed 
during pregnancy were given medications 
that are appropriate and safe for the fetus. 
Most of them received methyldopa (75%) and 
furosemide (75%) during the period before 
delivery. After delivery, all patients were given 
furosemide and bisoprolol. In patients who were 
diagnosed during the postpartum period, most 
were given furosemide, bisoprolol, and captopril. 
These are in concordance with the findings in a 
study on PPCM in Dr. Hasan Sadikin General 
Hospital Bandung during the period of 2011–
2013.13
Bromocriptine can be used to manage heart 
failure as it is able to inhibit prolactin so as to 
suppress lactation.1,4,13 This is based on the 
PPCM mechanism that is associated with the 
catabolism of prolactin.4,13 The recommended 
dose is 2.5 mg per day for 1 week and it should be 
given with heparin because this drug can cause 
thrombogenesis.1,4 In this study, two patients 
were given bromocriptine but only one patient 
was recorded as being given 2 doses of heparin 
prophylaxis 500 units subcutaneously.
Among the eight patients, there was one 
patient who had to be admitted to the high 
care unit. The patient experienced somnolence, 
delirium, and severe shortness of breath 
with a diagnosis of respiratory failure. She 
was intubated. On the third day, the patient’s 
condition improved and was transferred to the 
inpatient room.
All patients survived and were eventually 
discharged from the hospital after the cardiac 
decompensation had improved, the general 
condition was stable, and no complaints from the 
patients. The average length of stay was 9.5 days 
with 6 days as the shortest and 19 days as the 
longest. Decreased consciousness due to hypoxic 
encephalopathy was observed in patients with 
the longest length of stay.
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There is a high number of preeclampsia 
cases in Dr. Hasan Sadikin General Hospital 
Bandung, with a total of 767 cases in the period 
of 2017–2018. However, cases of PPCM and 
PPCM with preeclampsia are quite rare in this 
hospital. From 2017 to 2018, 40 PPCM patients 
were admitted with only eight (20%) of them 
were diagnosed with preeclampsia. A previous 
study shows that there are 20 PPCM with 
preeclampsia cases per 25 PPCM patients.11 With 
this reference, it can be stated that preeclampsia 
in the majority of PPCM patients in this hospital 
was detected and diagnosed. The incidence of 
preeclampsia in PPCM of this study is lower than 
that of the previous study in Surabaya which 
might be caused by a lack of exploration of the 
risk factors of patients diagnosed with PPCM. 
As a result, the diagnosis of preeclampsia is not 
made in patients with PPCM. Underdiagnosis 
might also be one of the reasons due to the fact 
that diagnosing patients with PPCM is quite 
challenging, especially in the antepartum period. 
The physiological state in the second trimester 
of pregnancy, which is the trimester with peak 
body fluid volume expansion, may complicate the 
diagnosis of pathologic heart problems because 
the clinical manifestations of body fluid volume 
expansion are similar to the manifestation of 
mild heart failure. In addition, not all patients 
with signs and symptoms of heart failure were 
consulted to the cardiologist, meaning that they 
are never examined for this condition and no 
echocardiography was performed, leading to 
underdiagnosis of PPCM among patients with 
preeclampsia.
This study has limitations because it is a 
retrospective study using secondary data from 
the patient's medical records in only one single 
center. The lack of control population and the 
inability to demonstrate a causal relationship 
between preeclampsia and peripartum 
cardiomyopathy also becomes another limitation 
of this study. 
In conclusion, cases of peripartum 
cardiomyopathy with preeclampsia are rarely 
reported in Dr. Hasan Sadikin General Hospital 
Bandung. In 2017–2018, there are 40 PPCM 
patients, with only eight (20%) diagnosed with 
preeclampsia. The diagnosis in PPCM patients 
requires a complete history taking, physical 
examination, and other diagnostic tests such 
as echocardiography. All patients analyzed 
(100%) complained of dyspnea on exertion as 
a chief complaint and 87.5% were included in 
functional class III–IV based on the New York 
Heart Association in 1994. The average ejection 
fraction was 34.6%, which indicates a value 
below the normal limit.
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